Interventional Therapy Plus Sorafenib in Patients with Limbs Alveolar Soft Tissue Sarcoma: a Report of 9 Cases

何新红,李文涛,彭卫军,袁正,李国栋,王升平,许立超,王耀辉

2013-01-01

Abstract:Objective To evaluate the efficacy and safety of interventional therapy combined with sorafenib in patients with limbs alveolar soft tissue sarcoma. Methods The clinical data of 9 cases of advanced limbs alveolar soft tissue sarcoma admitted between July 2007 and July 2010 in Fudan University Shanghai Cancer Center were analyzed retrospectively. All cases were obtained artery interventional embolism chemotherapy combined with sorafenib therapy. The efficacy,safety and prognosis survival situation were analyzed. Results After interventional embolism chemotherapy and sorafenib therapy,limbs primary lesions were not reduced significantly by MRI follow-up. But focal necrosis liquefied obviously and subjective symptoms improved including the pain relief or painkillers decrement,walking disorder or body activities obstacles eased. For the patients with lung or liver metastasis,the metastatic lesions got effective control,haemoptysis and cyanosis symptoms were alleviated obviously,and outdoor activities were increased. For the patients with multiple bone metastases,the bone pain symptoms have no obvious relief,and painkillers were still need to maintenance therapy. No serious adverse reaction related to interventional embolism chemotherapy and sorafenib therapy was observed in all patients,which needn’t adjustment of dose or interrupt treatment. Conclusion Interventional therapy combined with sorafenib therapy can relieve the tumor local symptoms and tumor related complications,improve quality of life significantly in patients with advanced limbs alveolar soft tissue sarcoma. The short-term survival benefit is good. It can be used as important supplement of the treatment for advanced limbs alveolar soft tissue sarcoma.